Role of circulating free DNA in colorectal cancer.

about

Role of circulating free DNA in colorectal cancer.

Item

http://www.wikidata.org/entity/Q39051652

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

Role of circulating free DNA in colorectal cancer.

@en

Role of circulating free DNA in colorectal cancer.

@nl

type

Item

label

Role of circulating free DNA in colorectal cancer.

@en

Role of circulating free DNA in colorectal cancer.

@nl

prefLabel

Role of circulating free DNA in colorectal cancer.

@en

Role of circulating free DNA in colorectal cancer.

@nl

P1476

Role of circulating free DNA in colorectal cancer.

@en

P2093

Alexandra Voutsina

http://www.w3.org/2001/XMLSchema#string

Alexios Matikas

http://www.w3.org/2001/XMLSchema#string

Maria Trypaki

http://www.w3.org/2001/XMLSchema#string

Vassilis Georgoulias

http://www.w3.org/2001/XMLSchema#string

P2860

Circulating tumor cells versus tumor-derived cell-free DNA: rivals or partners in cancer care in the era of single-cell analysis?

Amplification of the MET receptor drives resistance to anti-EGFR therapies in colorectal cancer

Activation of ERBB2 signaling causes resistance to the EGFR-directed therapeutic antibody cetuximab

Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer

Cell-free nucleic acids as noninvasive biomarkers for colorectal cancer detection

Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer.

K-ras mutations and benefit from cetuximab in advanced colorectal cancer.

Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer.

Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis.

Massively parallel tumor multigene sequencing to evaluate response to panitumumab in a randomized phase III study of metastatic colorectal cancer.

P304

810-818

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.4251/WJGO.V8.I12.810

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2016-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28035251

http://www.w3.org/2001/XMLSchema#string

P921

colorectal cancer

P932

5156847

http://www.w3.org/2001/XMLSchema#string